Business
BriaCell to Present Positive Clinical Data for Bria-IMT(TM) and Preclinical Data for Next Generation Bria-OTS+(TM) Personalized Immunotherapy at the 2026 AACR Conference
PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therape...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference\nPHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it will present four posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22 at the San Diego Convention Center in San Diego, California. The presentations will include one poster featuring data from BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612), two posters highlighting further analyses of Phase 2 data, and one poster presenting preclinical data related to Bria-OTS+, BriaCell’s next-generation personalized off-the-shelf immunotherapy for cancer. Abstracts will be published in the online Proceedings of the AACR. “With four posters presenting positive clinical and preclinical data, we are expanding the body of evidence supporting the efficacy and favorable safety profile of our novel immunotherapy, with the goal of improving care for patients with cancer who remain in urgent need of new treatment options,” stated William V. Williams, MD, BriaCell’s President & CEO. Session Title: Phase II and Phase III Clinical TrialsSession: 4/20/2026 2:00-5:00 PMLocation: Poster Section 52Poster Board Number: 1Poster Number: CT137 Title: QOL Outcomes in Bria-ABC Late-Stage Metastatic Phase 3 TrialSummary: Heavily pretreated metastatic breast cancer patients in the pivotal Phase 3 study of Bria-IMT plus an immune check point inhibitor maintained overall health status and key functional measures with a favorable safety profile. These findings are encouraging because they suggest meaningful preservation of quality of life for late-stage metastatic breast cancer patients with limited treatment options. Session Category: Clinical ResearchSession Title: Vaccines and Other Immunomodulatory AgentsSession: 4/21/2026 2:00-5:00 PMLocation: Poster Section 49Po...